|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| C07K 16/46 | (2006.01) | ||
| C12N 15/13 | (2006.01) |
| (11) | Number of the document | 2383297 |
| (13) | Kind of document | T |
| (96) | European patent application number | 11173336.6 |
| Date of filing the European patent application | 2007-08-14 | |
| (97) | Date of publication of the European application | 2011-11-02 |
| (45) | Date of publication and mention of the grant of the patent | 2013-01-16 |
| (46) | Date of publication of the claims translation | 2013-05-27 |
| (30) | Number | Date | Country code |
| 822362 P | 2006-08-14 | US |
| (72) |
Bernett, Matthew J., US
Chu, Seung Yup, US
Desjarlais, John R., US
Karki, Sher Bahadur, US
Lazar, Gregory Alan, US
Pong, Erik WeiKing, US
Richards, John O., US
Zhukovsky, Eugene Alexander, US
|
| (73) |
Xencor, Inc.,
465 North Halstead Street, Suite 200, Pasadena, CA 91107,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Optimizuoti antikūnai, kurie žymi CD19 |
| Optimized antibodies that target CD19 |
| Payment date | Validity (years) | Amount | |
| 2025-08-08 | 19 | 347.00 EUR |
| 2026-08-14 |